Generic Name and Formulations:
Sitagliptin (as phosphate) 25mg, 50mg, 100mg; tabs.

Company:
Merck & Co., Inc.
Indications for JANUVIA:
Adjunct to diet and exercise in type 2 diabetes, as monotherapy or combination therapy (see literature).

Adult Dose for JANUVIA:
100mg once daily. Renal insufficiency: CrCl ≥30–50mL/min: 50mg once daily; CrCl<30mL/min or on dialysis: 25mg once daily.

Children's Dose for JANUVIA:
<18yrs: not recommended.

Pharmacological Class:
Dipeptidyl peptidase-4 inhibitor.

Warnings/Precautions:
Not for the treatment of type 1 diabetes or diabetic ketoacidosis. Monitor renal function before starting therapy, then periodically. Monitor for pancreatitis; discontinue if it occurs. Severe hepatic insufficiency. Pregnancy (Cat.B). Nursing mothers.

Interactions:
Concomitant sulfonylurea or insulin: may need lower dose of sulfonylurea or insulin to reduce risk of hypoglycemia. Monitor digoxin.

Adverse Reactions:
Nasopharyngitis, upper respiratory tract infection, headache; hypersensitivity reactions (eg, anaphylaxis, angioedema, Stevens-Johnson syndrome), discontinue if occur.

How Supplied:
Tabs 25mg, 50mg—30, 90; 100mg—30, 90, 1000